Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

At the same time, our strong in-house R&D capabilities have put Alvotech in a leading position among pure play biosimilar companies in terms of the market value of our product pipeline. This ...

The company has already achieved its earlier goal of an "11-product biosimilar portfolio" in South Korea and Europe. Celltrion plans to finalize the approval procedures for its remaining pipeline ...

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab), following approval by the U.S. Food and ...

The company emphasized its strategic focus on biosimilars, noting significant investments and a robust pipeline targeting a $200 billion market. While Alvotech highlighted successful product launches ...

as the company expands its biosimilar pipeline. Amneal’s growth strategy heavily relies on new product launches and pipeline development. The recent launch of CREXONT has been particularly noteworthy.